Biotech Values

[DewDiligence]

…the rote statutory definitions - which are clearly not perfectly aligned with chemical reality.

The FDA’s dividing line between the NDA pathway and the BLA pathway, although arbitrary, is applied consistently. Peptides, sugars, and non-glycosylated proteins are reviewed as NDA’s, while glycoproteins are reviewed as BLA’s.